Could some breast cancer patients skip extra treatment? new trial investigates
NCT ID NCT07407920
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether patients with early HER2-positive or triple-negative breast cancer who had a complete response to pre-surgery treatment and have no cancer DNA in their blood can safely receive less therapy after surgery. The goal is to reduce side effects while keeping the cancer from coming back. The study involves 120 participants and uses drugs like pembrolizumab, trastuzumab, and pertuzumab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab, trastuzumab, pertuzumab, endocrine therapy
- What this could lead to
- If successful, this could show that some patients with early breast cancer can safely receive less treatment after surgery, reducing side effects while maintaining good outcomes.
- What could go wrong
- This is a small, early-phase trial (120 participants) and may not prove that reduced therapy is as effective as standard care. There is a risk that cancer could return without full treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?